Guardant Health and AI technology firm Trial Library have formed a strategic partnership aimed at improving access to cancer clinical studies across the US.
The partnership will integrate Guardant’s precision oncology diagnostics with Trial Library’s AI-driven patient matching and navigation platform.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is designed to increase trial participation among diverse and underserved patient groups by combining genomic data with personalised support and navigation services.
The two companies intend to simplify the process of identifying, referring, and enrolling patients into precision oncology studies, thereby allowing healthcare providers to provide new treatment opportunities to a wider patient base.
Guardant Health noted that its real-world data offerings, supported by a platform that has tested more than one million patients, will be used to recognise suitable candidates for trials based on biomarker and clinical information.
Trial Library’s platform is said to provide access to studies within community-based settings, spanning over 320 clinics and 1,500 providers across the country.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt uses AI to activate providers, identify eligible patients in compliance with regulations, and support patients throughout the trial process.
Trial Library CEO Dr Hala Borno said: “Trial Library’s collaboration with Guardant Health represents a powerful step forward in transforming genomic data into expanded trial access.
“By connecting test results to real-world trial opportunities and supporting patients through every step of the journey, we’re not only expanding trial participation but reshaping what equitable cancer care looks like.”
According to Guardant Health, more than 70% of patients are willing to take part in trials, but fewer than 7% of cancer patients currently enrol.
Barriers to participation are particularly high for those in underserved and rural areas, where awareness, logistical challenges, and limited trial infrastructure impede involvement. The alliance seeks to overcome these obstacles through new technologies.
In October 2025, Guardant Health entered a partnership with Zephyr AI to advance the discovery of new cancer biomarkers.
